



# Correction of previously published press release concerning the early publication of the quarterly report

The press release published on 18 October at 13.00 contains incorrect information, as the Quarterly Report 3 2021 has not been audited.

**For further information, please contact:**

Lumito's CEO, Mattias Lundin

e-mail: [ml@lumito.se](mailto:ml@lumito.se)

phone: 076-868 45 09

**Lumito** specializes in medical technology for digital pathology. Through its proprietary and patented technology, Lumito aims to provide healthcare providers with a powerful tool to meet the demands for fast and safe tissue diagnostics in personalized healthcare. The technology enables higher contrast images where unimportant background information is sorted out, making it easier for pathologists to find cancer indications. The technology, based on Up Converting Nano Particles (UCNP), has the potential to significantly improve the diagnosis of tissue samples through higher quality analyses and shorter analysis times. The method has several potential applications, but Lumito has chosen to focus primarily on digital pathology. The company is a spin-off from a research group at Lund University's Department of Atomic Physics and Laser Centre. [www.lumito.se](http://www.lumito.se).

The share is traded on NGM Nordic SME, under the name LUMITO and Mentor is Mangold Fondkommission, phone: 08-503 015 50.